Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

New fusion toxin with therapeutic potential in acute-phase CML presented at ASCO

May 29, 2000

Phase I trial of Hu1D10 continues following positive results in first lymphoma patients treated

May 29, 2000

Antisoma temporarily halts Theragyn phase III enrollment

May 29, 2000

News from ASCO: Medarex's MDX-210 may be useful in breast cancer and ovarian cancer

May 26, 2000

Vaccination with ras peptides as therapeutic strategy in pancreatic cancer

May 26, 2000

Cell Genesys reports encouraging preclinical data for leukemia vaccine

May 25, 2000

DSMB recommends continuation of Theratope phase III trial

May 22, 2000

Major approval obtained for Mylotarg, the first antibody-targeted chemotherapy product

May 19, 2000

Mechanism of action of OvaRex clarified

May 16, 2000

DSRB review supports continuation of Allovectin-7 trials

May 16, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...